Moleculin Biotech Inc. (NASDAQ:MBRX) said it remains on track to unblind the first set of data from its pivotal Phase 2B/3 ...

Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on ...

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, ...

Using the BLISS-LN phase 3 study of belimumab, investigators studied biomarker associations with kidney response in lupus nephritis.

Global Commercial Footprint -- Over 175 active sites are currently using ClearPoint technology, with expectations to surpass ...

Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...

Veru (NASDAQ:VERU) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the ...

Bank of America Global Healthcare Conference 2026 May 12, 2026 7:20 PM EDTCompany ParticipantsMegan Sniecinski ...

Operator: Good afternoon, and welcome to Relmada Therapeutics First Quarter Earnings Conference Call. At this time, all ...

Bank of America Global Healthcare Conference 2026 May 12, 2026 8:01 PM EDTCompany ParticipantsJeffrey Finer - Co-Founder, CEO ...

Diablo 4 players say randomized Unique affixes in Lord of Hatred can make rare loot feel messy, mismatched, and harder to ...

Orchestra BioMed (Nasdaq:OBIO) announced updated expectations for the timeline of its BACKBEAT cardiac pacing clinical trial.